Purpose of review: This review provides an update on recent developments in cell-based immunotherapy in gynecologic cancers.
Recent findings: Chimeric antigen receptor (CAR) technology has made significant progress allowing now for not only expressing CARs on T-cells, but also on other immune effector cells, such as natural killer cells and macrophages. Cell-based vaccines have started to show promising results in clinical trials.
Summary: Cell-based immunotherapies in gynecologic cancers continue to evolve with promising clinical efficacy in select patients.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.